Rongchang Biopharmaceutical (09995): Taitsop treatment of primary Sjogren's syndrome Phase III clinical study achieved primary research endpoint.

Zhtng Cijng APP news, Rngchng Shngw (09995) announced that the company's independently developed BLyS/APRIL dual-target fusion protein innovative drug Tacitinib (RC18, trade name: Tai'ai) for the treatment of primary Sjgren's syndrome (pSS) has achieved the primary research endpoints of the Phase III clinical trial as per the study design.